Genetic polymorphism of CYP1A2 in ethiopians affecting induction and expression: Characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1

Molecular Pharmacology

Volumn 64, Issue 3, 2003, Pages 659-669

  Aklillu, Eleni ^a   Carrillo, Juan Antonio ^b   Makonnen, Eyasu ^c   Hellman, Karin ^d   Pitarque, Maria ^a   Bertilsson, Leif ^d   Ingelman Sundberg, Magnus ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF EXTREMADURA   (Spain)

^c ADDIS ABABA UNIVERSITY   (Ethiopia)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; AFLATOXIN; CYTOCHROME P450 1A2;

ADULT; ARTICLE; CHEMICAL CARCINOGENESIS; COMPLEX FORMATION; DRUG METABOLISM; ENZYME SUBSTRATE; ETHIOPIA; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; GENE INDUCTION; GENETIC POLYMORPHISM; HAPLOTYPE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; OLIGONUCLEOTIDE PROBE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANALYSIS OF VARIANCE; BASE SEQUENCE; CYTOCHROME P-450 CYP1A2; ENZYME INDUCTION; ETHIOPIA; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HAPLOTYPES; HUMANS; INTRONS; LINKAGE (GENETICS); MOLECULAR SEQUENCE DATA; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; SWEDEN; TUMOR CELLS, CULTURED;

EID: 0042856457     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.64.3.659     Document Type: Article

References (40)

1. Aklillu E, Herrlin K, Gustafsson LL, Bertilsson L, and Ingelman-Sundberg M (2002a) Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. Pharmacogenetics 12:375-383.
2. Aklillu E, Oscarson M, Hidestrand M, Leidvik B, Otter C, and Ingelman-Sundberg M (2002b) Functional analysis ofsix different polymorphic CYP1B1 enzyme variants found in an Ethiopian population. Mol Pharmacol 61:586-594.
3. Basile VS, Ozdemir V, Masellis M, Walker ML, Meltzer HY, Lieberman JA, Potkin SG, Alva G, Kalow W, Macciardi FM, and Kennedy JL (2000) A functional polymorphism of the cytochrome P450 lA2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol Psychiatry 5:410-417.
4. Bertilsson L, Carrillo JA, Dahl ML, Llerena A, Alm C, Bondesson U, Lindstrom L, Rodriguez de la Rubia I, Ramos S, and Benitez J (1994) Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 38:471-473.
5. Carrillo JA, Christensen M, Ramos SI, Alm C, Dahl ML, Benitez J, and Bertilsson L (2000) Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva and urine. Ther Drug Monit 22:409-417.
6. Chida M, Yokoi T, Fukui T, Kinoshita M, Yokota J, and Kamataki T (1999) Detection of three genetic polymorphisms in the 5′-flanking region and intron 1 of human CYP1A2 in the Japanese population. Jpn J Cancer Res 90:899-902.
7. Chung I and Bresnick E (1995) Regulation of the constitutive expression of the human CYP1A2 gene: cis elements and their interactions with proteins. Mol Pharmacol 47:677-685.
8. Chung I and Bresnick E (1997) Identification of positive and negative regulatory elements of the human cytochrome P4501A2 (CYP1A2) gene. Arch Biochem Biophys 338:220-226.
9. Dittmer J and Nordheim A (1998) Ets transcription factors and human disease. Biochim Biophys Acta 1377:F1-F11.
10. Dwivedi PP, Omdahl JL, Kola I, Hume DA, and May BK (2000) Regulation of rat cytochrome P450C24 (CYP24) gene expression. Evidence for functional cooperation of Ras-activated Ets transcription factors with the vitamin D receptor in 1,25-dihydroxyvitamin D(3)-mediated induction. J Biol Chem 275:47-55.
11. Eaton DL, Gallagher EP, Bammler TK, and Kunze KL (1995) Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics 5:259-274.
12. Gallagher EP, Kunze KL, Stapleton PL, and Eaton DL (1996) The kinetics of aflatoxin B1 oxidation by human cDNA-expressed and human liver microsomal cytochromes P450 1A2 and 3A4. Toxicol Appl Pharmacol 141:595-606.
13. Ghadersohi A and Sood AK (2001) Prostate epithelium-derived Ets transcription factor mRNA is over-expressed in human breast tumors and is a candidate breast tumor marker and a breast tumor antigen. Clin Cancer Res 7:2731-2738.
14. Ikeya K, Jaiswal AK, Owens RA, Jones JE, Nebert DW, and Kimura S (1989) Human CYP1A2: sequence, gene structure, comparison with the mouse and rat orthologous gene and differences in liver lA2 mRNA expression. Mol Endocrinol 3:1399-1408.
15. Laumonnier Y, Nadaud S, Agrapart M, and Soubrier F (2000) Characterization of an upstream enhancer region in the promoter of the human endothelial nitric-oxide synthase gene. J Biol Chem 275:40732-40741.
16. Le Jossic C, Glaise D, Corcos L, Diot C, Dezier JF, Fautrel A, and Guguen-Guillouzo C (1996) trans-Acting factors, detoxication enzymes and hepatitis B virus replication in a novel set of human hepatoma cell lines. Eur J Biochem 238:400-409.
17. McLellan RA, Oscarson M, Seidegard J, Evans DA, and Ingelman-Sundberg M (1997) Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 7:187-191.
18. McManus ME, Burgess WM, Veronese ME, Huggett A, Quattrochi LC, and Tukey RH (1990) Metabolism of 2-acetylaminofluorene and benzo(a)pyrene and activation of food-derived heterocyclic amine mutagens by human cytochromes P-450. Cancer Res 50:3367-3376.
19. Minchin RF, McManus ME, Boobis AR, Davies DS, and Thorgeirsson SS (1985) Polymorphic metabolism of the carcinogen 2-acetylaminofluorene in human liver microsomes. Carcinogenesis 6:1721-1724.
20. Mullick J, Anandatheerthavarada HK, Amuthan G, Bhagwat SV, Biswas G, Camasamudram V, Bhat NK, Reddy SE, Rao V, and Avadhani NG (2001) Physical interaction and functional synergy between glucocorticoid receptor and Ets2 proteins for transcription activation of the rat cytochrome P-450c27 promoter. J Biol Chem 276:18007-18017.
21. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, and Kamataki T (1999) Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans, J Biochem (Tokyo) 125:803-808.
22. Nakajima M, Yokoi T, Mizutani M, Shin S, Kadlubar FF, and Kamataki T (1994) Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol Biomarkers Prev 3:413-421.
23. Nordmark A, Lundgren S, Ask B, Granath F, and Rane A (2002) The effect of the CYP1A2 ′1F mutation on CYP1A2 inducibility in pregnant women. Br J Clin Pharmacol 54:504-510.
24. Oscarson M, Gullsten H, Rautio A, Bernal ML, Sinues B, Dahl ML, Stengard JH, Pelkonen O, Raunio H, and Ingelman-Sundberg M (1998) Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. FEBS Lett 438:201-205.
25. Ozaki I, Mizuta T, Zhao G, Yotsumoto H, Hara T, Kajihara S, Hisatomi A, Sakai T, and Yamamoto K (2000) Involvement of the Ets-1 gene in overexpression of matrilysin in human hepatocellular carcinoma. Cancer Res 60:6519-6525.
26. Phillips KA, Veenstra DL, Oren E, Lee JK, and Sadee W (2001) Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA (J Am Med Assoc) 286:2270-2279.
27. Quattrochi LC, Shih H, and Pickwell GV (1998) Induction of the human CYP1A2 enhancer by phorbol ester. Arch Biochem Biophys 350:41-48.
28. Quattrochi LC, Vu T, and Tukey RH (1994) The human CYP1A2 gene and induction by 3-methylcholanthrene. A region of DNA that supports AH AH-receptor binding and promoter-specific induction. J Biol Chem 269:6949-6954.
29. Rasmussen BB, Brix TH, Kyvik KO, and Brosen K (2002) The interindividual differences in the 3-demethylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics 12:473-478.
30. Sachse C, Brockmoller J, Bauer S, and Roots I (1999) Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47:445-449.
31. Schmidt JV, Su GH, Reddy JK, Simon MC, and Bradfield CA (1996) Characterization of a murine Ahr null allele: involvement of the Ah receptor in hepatic growth and development. Proc Natl Acad Sci USA 93:6731-6736.
32. Schrenk D, Brockmeier D, Morike K, Bock KW, and Eichelbaum M (1998) A distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy Caucasian volunteers. Eur J Clin Pharmacol 53:361-367.
33. Schulze TG, Schumacher J, Muller DJ, Krauss H, Alfter D, Maroldt A, Ahle G, Maroldt AO, Novo y Fernandez A, Weber T, et al. (2001) Lack of association between a functional polymorphism of the cytochrome P450 lA2 (CYP1A2) gene and tardive dyskinesia in schizophrenia. Am J Med Genet 105:498-501.
34. Shimoda K, Someya T, Morita S, Hirokane G, Yokono A, Takahashi S, and Okawa M (2002) Lack of impact of CYP1A2 genetic polymorphism (C/A polymorphism at position 734 in intron 1 and G/A polymorphism at position -2964 in the 5′-flanking region of CYP1A2) on the plasma concentration of haloperidol in smoking male Japanese with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 26:261-265.
35. Sofowora GG, Choo EF, Mayo G, Shyr Y, and Wilkinson GR (2001) In vivo inhibition of human CYP1A2 activity by oltipraz. Cancer Chemother Pharmacol 47:505-510.
36. Sogawa K, Nakano R, Kobayashi A, Kikuchi Y, Ohe N, Matsushita N, and Fujii-Kuriyama Y (1995) Possible function of Ah receptor nuclear translocator (Arnt) homodimer in transcriptional regulation. Proc Natl Acad Sci USA 92:1936-1940.
37. Uwaifo AO and Bababunmi EA (1984) Liver carcinogenesis in tropical Africa. IARC Sci Publ 63:59-88.
38. Wooding SP, Watkins WS, Bamshad MJ, Dunn DM, Weiss RB, and Jorde LB (2002) DNA sequence variation in a 3.7-kb noncoding sequence 5′ of the Cyp1A2 gene: implications for human population history and natural selection. Am J Hum Genet 71:528-542.
39. Yokomori N, Kobayashi R, Moore R, Sueyoshi T, and Negishi M (1995) A DNA methylation site in the male-specific P450 (Cyp 2d-9) promoter and binding of the heteromeric transcription factor GABP. Mol Cell Biol 15:5355-5362.
40. Zhu Y and Pfaff DW (1994) Protein-DNA-binding assay for analysis of steroidsensitive neurons in mammalian brain. Methods Neurosci 22:245-264.